Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform

|

|

Last update:

  • Increases total equity financing raised to £7.2M ($10.1M)
  • New facilities in Boston and Prague will provide increased capacity to deliver pipeline of pharma and biotech projects
  • Funding to progress internal assets targeting multiple GPCRs and Ion Channels towards clinical trials

CARDIFF, Wales–(BUSINESS WIRE)–Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many in partnership with pharmaceutical companies. The latest investment round was led by i&i Biotech Fund I (i&i Bio) and Kadmos Capital, with additional investment from existing investors InnoSpark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, and AngelHub. This brings the total equity financing raised to £7.2M ($10.1M).


The funding will be used to expand the Company’s laboratory and machine learning teams, bolstering the development of its internal assets against G-protein-coupled receptors (GPCRs) and ion channels towards the clinic, as well as facilitating ongoing collaborations with pharma and biotech companies. The funding will also be used to improve the predictive accuracy of the design platform, focusing on curating training data. Lastly, Antiverse has opened new facilities in Boston, MA, and Prague, Czech Republic, demonstrating its expansion.

Antiverse uses a machine-learning-centred approach to design antibodies for challenging targets, helping to bring needed therapies to patients. The current version of the platform uses ‘target-specific libraries’. These libraries are designed by using structural and sequence data to generate a library with high confidence against the target. This enhances the predictive accuracy compared to traditional antibody libraries, enabling Antiverse to design antibodies for many challenging targets, including GPCRs and ion channels. The platform accelerates the antibody discovery process to 6 months.

Murat Tunaboylu, Co-Founder and CEO of Antiverse said: “A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe.”

Jaromir Zahradka, CEO at i&i Bio, commented: “Antiverse has made significant progress in the field of antibody design. Antiverse’s mission to make GPCRs druggable focuses on a key issue and we are pleased to be supporting them.”

John Gebeily, Operating Partner at Kadmos Capital, added: “Antiverse’s AI-driven antibody design platform demonstrates significant potential in advancing the development of novel antibody therapeutics, particularly for complex drug targets. We’re excited to support Murat and the team in their effort to significantly accelerate the development of life-saving treatments, and have a transformative impact on the pharmaceutical industry.”

Contacts

Media:
Dr Ben Rutter

Zyme Communications

Tel: +44(0)7920 770 935

Email: [email protected]

Topics:

Follow us:

Business Wire

Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure.Public relations, investor relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.Founded in 1961, Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX network. Business Wire’s global newsrooms are available to meet the needs of communications professionals and news media worldwide.

Partner eventsMore events

Current Month

04jun2:00 pm3:00 pmSigli’s free webinar “The AI Profit Toolkit”Helping European SMEs navigate AI profitability

05jun5:45 am8:00 pmSwitching Careers into Tech in 2025Thinking about making a move into tech? 2025 might be the year to do it.

19junAll Day20TNW Conference

Share to...